2022
Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)
Johnson B, Haymaker C, Parra E, Soto L, Wang X, Thomas J, Dasari A, Morris V, Raghav K, Vilar E, Kee B, Eng C, Parseghian C, Wolff R, Lee Y, Lorenzini D, Laberiano-Fernandez C, Verma A, Lang W, Wistuba I, Futreal A, Kopetz S, Overman M. Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). Journal For ImmunoTherapy Of Cancer 2022, 10: e005332. PMID: 36007963, PMCID: PMC9422817, DOI: 10.1136/jitc-2022-005332.Peer-Reviewed Original ResearchConceptsMicrosatellite stable (MSS) metastatic colorectal cancerTreatment-related adverse eventsMetastatic colorectal cancerResponse rateStable diseasePartial responsePD-1Lung metastasesColorectal cancerT cellsCommon treatment-related adverse eventsMedian age 48 yearsMedian progression-free survivalTumor microenvironmentCombination of trametinibPhase II studyPhase II trialProgression-free survivalCD8 T cellsImmune checkpoint blockadeT cell infiltrationImmune tumor microenvironmentOverall response rateAge 48 yearsComparison of baseline
2018
Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment
Wong Y, Joshi K, Khetrapal P, Ismail M, Reading J, Sunderland M, Georgiou A, Furness A, Aissa A, Ghorani E, Oakes T, Uddin I, Tan W, Feber A, McGovern U, Swanton C, Freeman A, Marafioti T, Briggs T, Kelly J, Powles T, Peggs K, Chain B, Linch M, Quezada S. Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment. Journal Of Experimental Medicine 2018, 215: 2748-2759. PMID: 30257862, PMCID: PMC6219732, DOI: 10.1084/jem.20181003.Peer-Reviewed Original ResearchConceptsMuscle invasive bladder cancerImmune tumor microenvironmentTumor microenvironmentImmuno-oncologyT cellsBladder cancerExpression of PD-1Response to checkpoint blockadeShorter recurrence-free survivalT cell receptor repertoireSource of T cellsEffector CD8<sup>+</sup>Recurrence-free survivalInvasive bladder cancerRegulatory T cellsTumor immune microenvironmentCD4<sup>+</sup> cellsFraction of patientsImmunotherapy combinationsCheckpoint blockadePD-1Cancer immunotherapyCD8<sup>+</sup>Immune microenvironmentPrognostic value
2017
Tumor-associated macrophages, nanomedicine and imaging: the axis of success in the future of cancer immunotherapy
Zanganeh S, Spitler R, Hutter G, Ho J, Pauliah M, Mahmoudi M. Tumor-associated macrophages, nanomedicine and imaging: the axis of success in the future of cancer immunotherapy. Immunotherapy 2017, 9: 819-835. PMID: 28877626, DOI: 10.2217/imt-2017-0041.Peer-Reviewed Original ResearchConceptsTumor-associated macrophagesTumor microenvironmentCancer immunotherapyTargeting of tumor-associated macrophagesTAM modulationImmune tumor microenvironmentIndividualized cancer therapyTarget specific cell typesInfluence tumor microenvironmentImprove treatment efficacyTheranostic probesModulate immune functionNucleic acid deliveryMultimodal imaging strategyTumor responseImmunotherapeutic interventionsSpecific cell typesSolid tumorsImmune cellsTranslational research approachTreatment optionsClinical trialsImproved biomarkersCancer therapyImmunotherapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply